Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the EBMT
| dc.contributor.author | Kharfan-Dabaja MA | |
| dc.contributor.author | Labopin M | |
| dc.contributor.author | Ayala E | |
| dc.contributor.author | Bazarbachi A | |
| dc.contributor.author | Blaise D | |
| dc.contributor.author | Vydra J | |
| dc.contributor.author | Bramanti S | |
| dc.contributor.author | Itala-Remes M | |
| dc.contributor.author | Schmid C | |
| dc.contributor.author | Busca A | |
| dc.contributor.author | Forcade E | |
| dc.contributor.author | Rabitsch W | |
| dc.contributor.author | Zecca M | |
| dc.contributor.author | Kroger N | |
| dc.contributor.author | Bulabois CE | |
| dc.contributor.author | Grillo G | |
| dc.contributor.author | Rambaldi A | |
| dc.contributor.author | Fanin R | |
| dc.contributor.author | Zallio F | |
| dc.contributor.author | Di Renzo N | |
| dc.contributor.author | Koc Y | |
| dc.contributor.author | Novis Y | |
| dc.contributor.author | McDonald A | |
| dc.contributor.author | Arroyo CH | |
| dc.contributor.author | Sanz J | |
| dc.contributor.author | Nagler A | |
| dc.contributor.author | Ciceri F | |
| dc.contributor.author | Mohty M | |
| dc.contributor.organization | fi=sisätautioppi|en=Internal Medicine| | |
| dc.contributor.organization | fi=tyks, vsshp|en=tyks, varha| | |
| dc.contributor.organization-code | 1.2.246.10.2458963.20.40502528769 | |
| dc.converis.publication-id | 180395439 | |
| dc.converis.url | https://research.utu.fi/converis/portal/Publication/180395439 | |
| dc.date.accessioned | 2025-08-28T00:49:48Z | |
| dc.date.available | 2025-08-28T00:49:48Z | |
| dc.description.abstract | <p>Availability of haploidentical donors has broadened utilization of allogeneic hematopoietic cell transplantation (allo-HCT). Peripheral blood stem cells (PBSC) are being used with increased frequency in haploidentical allo-HCT. We evaluated extent of HLA disparity (2-3/8 versus 4/8 HLA antigen mismatches) on post-allograft outcomes when using T-cell replete PBSC from haploidentical donors for acute myeloid leukemia in first complete remission. Primary objectives entailed assessing cumulative incidence of grade 2-4 acute graft -versus-host disease (GVHD) and chronic GVHD (any grade). A total of 645 patients received a haploidentical allo-HCT from a donor with either 2-3 of 8 HLA antigen mismatches (n = 180) or with 4 of 8 HLA antigen mismatches (n = 465). Presence of 2-3 of 8 versus 4 of 8 HLA mismatches did not affect the incidence of acute GVHD (grade 2-4) and chronic GVHD (any grade). Overall survival (OS), leukemia-free survival (LFS) relapse incidence (RI), nonrelapse mortality and the composite endpoint of GVHD-free relapse-free survival were also similar among the groups. Pertaining to HLA-B leader matching effect, our analysis did not discern any difference in aforementioned post-allograft outcomes for this variable. However, in univariate analysis, absence of an antigen mismatch in HLA-DPB1 showed a trend for better OS. Notwithstanding inherent limitations associated with registry data, our results did not show an advantage of selecting a haploidentical donor with 2-3 of 8 HLA antigen mismatches over one with 4 of 8 HLA antigen mismatches when using PBSC as the cell source. Adverse cytogenetics remains a major adverse determinant of inferior OS and LFS and a higher RI. Using reduced-intensity conditioning yielded worse OS and LFS.<br></p> | |
| dc.identifier.eissn | 2572-9241 | |
| dc.identifier.jour-issn | 2572-9241 | |
| dc.identifier.olddbid | 206495 | |
| dc.identifier.oldhandle | 10024/189522 | |
| dc.identifier.uri | https://www.utupub.fi/handle/11111/46872 | |
| dc.identifier.url | https://journals.lww.com/hemasphere/Fulltext/2023/07000/Significance_of_Degree_of_HLA_Disparity_Using.6.aspx | |
| dc.identifier.urn | URN:NBN:fi-fe2025082787376 | |
| dc.language.iso | en | |
| dc.okm.affiliatedauthor | Itälä-Remes, Maija | |
| dc.okm.affiliatedauthor | Dataimport, tyks, vsshp | |
| dc.okm.discipline | 3121 Internal medicine | en_GB |
| dc.okm.discipline | 3122 Cancers | en_GB |
| dc.okm.discipline | 3121 Sisätaudit | fi_FI |
| dc.okm.discipline | 3122 Syöpätaudit | fi_FI |
| dc.okm.internationalcopublication | international co-publication | |
| dc.okm.internationality | International publication | |
| dc.okm.type | A1 ScientificArticle | |
| dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | |
| dc.publisher.country | United States | en_GB |
| dc.publisher.country | Yhdysvallat (USA) | fi_FI |
| dc.publisher.country-code | US | |
| dc.relation.articlenumber | e920 | |
| dc.relation.doi | 10.1097/HS9.0000000000000920 | |
| dc.relation.ispartofjournal | HemaSphere | |
| dc.relation.issue | 7 | |
| dc.relation.volume | 7 | |
| dc.source.identifier | https://www.utupub.fi/handle/10024/189522 | |
| dc.title | Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the EBMT | |
| dc.year.issued | 2023 |
Tiedostot
1 - 1 / 1
Ladataan...
- Name:
- Significance_of_Degree_of_HLA_Disparity_Using.6.pdf
- Size:
- 1.18 MB
- Format:
- Adobe Portable Document Format